Edition:
United Kingdom

WAVE Life Sciences Ltd (WVE.OQ)

WVE.OQ on NASDAQ Stock Exchange Global Market

46.10USD
15 Aug 2018
Change (% chg)

$-0.15 (-0.32%)
Prev Close
$46.25
Open
$46.15
Day's High
$46.15
Day's Low
$44.25
Volume
52,012
Avg. Vol
60,940
52-wk High
$55.95
52-wk Low
$16.10

Latest Key Developments (Source: Significant Developments)

Wave Life Sciences Ltd Reports Qtrly Loss Per Share Of $1.23
Thursday, 9 Aug 2018 

Aug 9 (Reuters) - WAVE Life Sciences Ltd ::WAVE LIFE SCIENCES REPORTS SECOND QUARTER 2018 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE.ENDED Q2 OF 2018 WITH $241.4 MILLION IN CASH AND CASH EQUIVALENTS.EXPECTS THAT ITS CASH POSITION WILL ENABLE IT TO FUND ITS OPERATING AND CAPITAL EXPENDITURE REQUIREMENTS TO END OF 2020.QTRLY REVENUE $4.9 MILLION VERSUS $1.1 MILLION.QTRLY LOSS PER SHARE $1.23.Q2 EARNINGS PER SHARE VIEW $-0.55 -- THOMSON REUTERS I/B/E/S.  Full Article

Wave Life Sciences Reports Qtrly Loss Per Share $1.26
Wednesday, 9 May 2018 

May 9 (Reuters) - WAVE Life Sciences Ltd ::WAVE LIFE SCIENCES REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE.WAVE LIFE SCIENCES LTD QTRLY LOSS PER SHARE $1.26.WAVE LIFE SCIENCES LTD - ENDED Q1 OF 2018 WITH $110.5 MILLION IN CASH AND CASH EQUIVALENTS.WAVE LIFE SCIENCES - EXPECTS CASH, CASH EQUIVALENTS, $170.0 MILLION CASH FROM TAKEDA IN APRIL, ENABLE FUNDING OPERATING, CAPEX REQUIREMENTS TO 2020 END.  Full Article

Wave Life Ended 2017 With $142.5 Mln In Cash, Equivalents
Monday, 12 Mar 2018 

March 12 (Reuters) - Wave Life Sciences Ltd ::WAVE LIFE SCIENCES REPORTS FOURTH QUARTER AND FULL-YEAR 2017 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE.WAVE LIFE SCIENCES LTD - ENDED 2017 WITH $142.5 MILLION IN CASH AND CASH EQUIVALENTS.WAVE LIFE SCIENCES - EXPECTS CASH AND CASH EQUIVALENTS, COMMITTED CASH FROM COLLABORATION WITH TAKEDA, TO FUND REQUIREMENTS TO END OF 2020.  Full Article

Wave Life Sciences Reports Data From Preclinical Studies Testing WVE-3972-01
Monday, 11 Dec 2017 

Dec 11 (Reuters) - Wave Life Sciences Ltd ::WAVE LIFE SCIENCES - ANNOUNCED DATA FROM PRECLINICAL STUDIES OF WVE-3972-01 FOR TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS AND FRONTOTEMPORAL DEMENTIA.WAVE LIFE SCIENCES - WVE-3972-01 DEMONSTRATED SUBSTANTIAL REDUCTION IN DISEASE-ASSOCIATED BIOMARKERS & SUPERIOR POTENCY TO STEREORANDOM OLIGONUCLEOTIDES.WAVE LIFE SCIENCES LTD - CO INTENDS TO INITIATE CLINICAL TRIALS OF WVE-3972-01 IN ALS AND FTD IN Q4 2018.  Full Article

Wave Life Sciences Q3 net loss of $26.1 million
Thursday, 9 Nov 2017 

Nov 9 (Reuters) - Wave Life Sciences Ltd ::Wave Life Sciences reports third quarter 2017 financial results and provides business update.Wave Life Sciences Ltd - ‍ Wave reported a net loss of $26.1 million for Q3 of 2017, as compared to a net loss of $17.5 million for Q3 of 2016​.Wave Life Sciences Ltd - qtrly loss per share $0.94‍​.Wave Life Sciences -‍ expects capital resources available, anticipated milestone payments to be sufficient to fund expenses, capex needs into mid-2019​.  Full Article

Wave Life Sciences initiates clinical trial for lead program in Duchenne muscular dystrophy
Monday, 6 Nov 2017 

Nov 6 (Reuters) - Wave Life Sciences Ltd :Wave Life Sciences initiates clinical trial for lead program in Duchenne muscular dystrophy (DMD).Wave Life Sciences Ltd - ‍data from phase 1 trial for WVE-210201 are expected in Q3 2018​.  Full Article

Teva pharmaceutical reports 5 pct stake in Wave Life Sciences as of Aug 30, 2017 versus 9 percent stake as of Nov 16, 2015
Tuesday, 5 Sep 2017 

Sept 6 (Reuters) - Teva Pharmaceutical Industries Ltd :Teva Pharmaceutical Industries Limited reports 5 percent stake in Wave Life Sciences Ltd as of Aug 30, 2017 versus 9 percent stake as of Nov 16, 2015 - SEC filing‍​.  Full Article

Wave Life Sciences qtrly loss per share $0.92‍​
Wednesday, 9 Aug 2017 

Aug 9 (Reuters) - Wave Life Sciences Ltd ::Wave life sciences reports second quarter 2017 financial results and provides business update.Wave life sciences ltd qtrly loss per share $0.92‍​.Wave life sciences - ‍expects cash, cash equivalents available as of June 30, milestone payments, will be sufficient to fund co's operations into mid-2019​.  Full Article

Wave Life Sciences initiates two Phase 1b/2a clinical trials PRECISION-HD1 and PRECISION-HD2 in patients with Huntington’S Disease
Monday, 17 Jul 2017 

July 17 (Reuters) - Wave Life Sciences Ltd :Wave Life Sciences Ltd - ‍trials evaluate first allele-specific investigational drugs for Huntington's Disease, WVE-120101 and WVE-120102​.  Full Article

Readcoor and Wave Life Sciences initiate research collaboration
Thursday, 8 Jun 2017 

June 8 (Reuters) - Wave Life Sciences Ltd ::Readcoor and Wave Life Sciences initiate research collaboration.Wave Life Sciences Ltd says collaboration aims to unlock next generation stereopure nucleic acid targets with Novel Fisseq Technologies.  Full Article

BRIEF-Wave Life Sciences Reports Qtrly Loss Per Share $1.26

* WAVE LIFE SCIENCES REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE